Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715793 | 0.95 | NMT2 (0.49) | NMT2NMT1C3AR1NOD1SLC6A5 | |
| SCHEMBL24193304 | 0.92 | C3AR1 (0.42) | NMT2NMT1C3AR1NOD1SLC6A5 | |
| SCHEMBL29485106 | 0.91 | NPY4R (0.43) | NMT2NMT1NOD1SLC6A5FURIN | |
| SCHEMBL29819426 | 0.91 | NOD1 (0.54) | NOD1SLC6A5FURINCTSLEPHX2 | |
| SCHEMBL20800175 | 0.90 | GNPAT (0.49) | C3AR1NOD1FURINFNTAFNTB | |
| SCHEMBL29385639 | 0.90 | C3AR1 (0.45) | C3AR1NOD1FURINFOLH1CPB2 | |
| SCHEMBL30018681 | 0.90 | NOD1 (0.56) | NOD1SLC6A5FURINCTSLEPHX2 | |
| SCHEMBL21607789 | 0.89 | C3AR1 (0.43) | C3AR1NOD1FURINFNTAFNTB | |
| SCHEMBL26223141 | 0.89 | C3AR1 (0.43) | C3AR1NOD1FURINFNTAFNTB | |
| SCHEMBL16801582 | 0.86 | C3AR1 (0.40) | C3AR1NOD1SLC6A5FURINFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4213886-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | Araris Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | NMT2 112/4885NMT1 92/4885C3AR1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.